PepGen Inc. (PEPG) Stock

PepGen Inc. (PEPG) is a Healthcare stock trading at $1.79 (as of 2026-06-18), with a market capitalization of $103.75M and a trailing P/E of -1.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide-based therapeutics aimed at severe neuromuscular and neurologic diseases. Its pipeline includes PGN-EDO51, an EDO peptide in Phase I for Duchenne muscular dystrophy, and PGN-EDODM1, an EDO peptide-conjugated PMO for myotonic dystrophy type 1, along with additional EDO therapeutic candidates for Duchenne.

Valuation — source: SEC EDGAR (first-party)
Price	$1.79
Market Cap	$103.75M
P/E Ratio	-1.0
EV / EBITDA	-0.8
Price / Book	0.77
DCF Value (model)	$-19.30
DCF Upside vs Price	-1175.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.02M
Net Margin	-2231.9%
Return on Equity	-57.6%
Current Ratio	14.98
Revenue Growth (YoY)	-43.8%
EPS Growth (YoY)	-25.6%
FCF Growth (YoY)	-1.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.89 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.0
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-104.9%
vs Industry	-106.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($35.51M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	James G. McArthur
Employees	79
Country	US
IPO Date	2022-05-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.